S&P 500   4,447.88 (-0.02%)
DOW   34,760.38 (-0.01%)
QQQ   371.20 (-0.48%)
AAPL   146.04 (-0.54%)
MSFT   297.79 (-0.59%)
FB   347.16 (+0.35%)
GOOGL   2,832.99 (+0.31%)
TSLA   752.11 (-0.20%)
AMZN   3,403.10 (-0.38%)
NVDA   219.62 (-2.31%)
BABA   145.09 (-4.03%)
NIO   35.31 (-1.94%)
CGC   13.96 (-4.12%)
GE   103.52 (+0.54%)
MU   74.24 (+0.27%)
AMD   105.22 (-0.88%)
T   27.32 (+0.48%)
F   13.87 (+1.17%)
ACB   6.00 (-2.44%)
DIS   175.98 (-0.15%)
PFE   44.29 (+0.23%)
BA   221.85 (+0.34%)
BAC   42.19 (+1.20%)
S&P 500   4,447.88 (-0.02%)
DOW   34,760.38 (-0.01%)
QQQ   371.20 (-0.48%)
AAPL   146.04 (-0.54%)
MSFT   297.79 (-0.59%)
FB   347.16 (+0.35%)
GOOGL   2,832.99 (+0.31%)
TSLA   752.11 (-0.20%)
AMZN   3,403.10 (-0.38%)
NVDA   219.62 (-2.31%)
BABA   145.09 (-4.03%)
NIO   35.31 (-1.94%)
CGC   13.96 (-4.12%)
GE   103.52 (+0.54%)
MU   74.24 (+0.27%)
AMD   105.22 (-0.88%)
T   27.32 (+0.48%)
F   13.87 (+1.17%)
ACB   6.00 (-2.44%)
DIS   175.98 (-0.15%)
PFE   44.29 (+0.23%)
BA   221.85 (+0.34%)
BAC   42.19 (+1.20%)
S&P 500   4,447.88 (-0.02%)
DOW   34,760.38 (-0.01%)
QQQ   371.20 (-0.48%)
AAPL   146.04 (-0.54%)
MSFT   297.79 (-0.59%)
FB   347.16 (+0.35%)
GOOGL   2,832.99 (+0.31%)
TSLA   752.11 (-0.20%)
AMZN   3,403.10 (-0.38%)
NVDA   219.62 (-2.31%)
BABA   145.09 (-4.03%)
NIO   35.31 (-1.94%)
CGC   13.96 (-4.12%)
GE   103.52 (+0.54%)
MU   74.24 (+0.27%)
AMD   105.22 (-0.88%)
T   27.32 (+0.48%)
F   13.87 (+1.17%)
ACB   6.00 (-2.44%)
DIS   175.98 (-0.15%)
PFE   44.29 (+0.23%)
BA   221.85 (+0.34%)
BAC   42.19 (+1.20%)
S&P 500   4,447.88 (-0.02%)
DOW   34,760.38 (-0.01%)
QQQ   371.20 (-0.48%)
AAPL   146.04 (-0.54%)
MSFT   297.79 (-0.59%)
FB   347.16 (+0.35%)
GOOGL   2,832.99 (+0.31%)
TSLA   752.11 (-0.20%)
AMZN   3,403.10 (-0.38%)
NVDA   219.62 (-2.31%)
BABA   145.09 (-4.03%)
NIO   35.31 (-1.94%)
CGC   13.96 (-4.12%)
GE   103.52 (+0.54%)
MU   74.24 (+0.27%)
AMD   105.22 (-0.88%)
T   27.32 (+0.48%)
F   13.87 (+1.17%)
ACB   6.00 (-2.44%)
DIS   175.98 (-0.15%)
PFE   44.29 (+0.23%)
BA   221.85 (+0.34%)
BAC   42.19 (+1.20%)
NASDAQ:PCRX

Pacira BioSciences Stock Forecast, Price & News

$58.00
+0.01 (+0.02 %)
(As of 09/24/2021 10:18 AM ET)
Add
Compare
Today's Range
$57.40
$58.03
50-Day Range
$54.64
$61.30
52-Week Range
$48.23
$80.00
Volume606 shs
Average Volume437,505 shs
Market Capitalization$2.58 billion
P/E Ratio14.83
Dividend YieldN/A
Beta1.07
30 days | 90 days | 365 days | Advanced Chart
Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.


Pacira BioSciences logo

About Pacira BioSciences

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.30 out of 5 stars

Medical Sector

249th out of 1,351 stocks

Pharmaceutical Preparations Industry

121st out of 664 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Pacira BioSciences (NASDAQ:PCRX) Frequently Asked Questions

Is Pacira BioSciences a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Pacira BioSciences stock.
View analyst ratings for Pacira BioSciences
or view top-rated stocks.

What stocks does MarketBeat like better than Pacira BioSciences?

Wall Street analysts have given Pacira BioSciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pacira BioSciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Pacira BioSciences' next earnings date?

Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Pacira BioSciences
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its quarterly earnings data on Monday, August, 2nd. The company reported $0.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.03. The business earned $135.60 million during the quarter, compared to the consensus estimate of $135.02 million. Pacira BioSciences had a net margin of 34.60% and a trailing twelve-month return on equity of 14.35%. Pacira BioSciences's revenue for the quarter was up 79.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.12 EPS.
View Pacira BioSciences' earnings history
.

How has Pacira BioSciences' stock price been impacted by COVID-19 (Coronavirus)?

Pacira BioSciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PCRX stock has increased by 64.8% and is now trading at $57.99.
View which stocks have been most impacted by COVID-19
.

What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences issued an update on its second quarter 2021 earnings guidance on Tuesday, August, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.60 million-$135.60 million, compared to the consensus revenue estimate of $128.01 million.

What price target have analysts set for PCRX?

11 brokers have issued twelve-month price targets for Pacira BioSciences' shares. Their forecasts range from $66.00 to $94.00. On average, they anticipate Pacira BioSciences' stock price to reach $80.08 in the next twelve months. This suggests a possible upside of 38.1% from the stock's current price.
View analysts' price targets for Pacira BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Pacira BioSciences' key executives?

Pacira BioSciences' management team includes the following people:
  • David M. Stack, Chairman, Chief Executive & Operating Officer
  • Charles A. Reinhart, Chief Financial Officer
  • Roy Winston, Chief Medical Officer (LinkedIn Profile)
  • Charles Anthony Laranjeira, Chief Technical Officer
  • Jonathan Slonin, Chief Clinical Officer

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences CEO Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among Pacira BioSciences' employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.98%), Vanguard Group Inc. (10.63%), Macquarie Group Ltd. (8.36%), Baillie Gifford & Co. (4.78%), Renaissance Technologies LLC (4.63%) and State Street Corp (3.32%). Company insiders that own Pacira BioSciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Donald C Manning, John P Phd Longenecker, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends for Pacira BioSciences
.

Which institutional investors are selling Pacira BioSciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Frontier Capital Management Co. LLC, Rice Hall James & Associates LLC, Tamarack Advisers LP, Lisanti Capital Growth LLC, Paulson & CO. Inc., and Legal & General Group Plc. Company insiders that have sold Pacira BioSciences company stock in the last year include Andreas Wicki, Charles A Reinhart III, David M Stack, Donald C Manning, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences
or view top insider-selling stocks.

Which institutional investors are buying Pacira BioSciences stock?

PCRX stock was purchased by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Macquarie Group Ltd., Vanguard Group Inc., Dimensional Fund Advisors LP, Nuveen Asset Management LLC, MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income, Tygh Capital Management Inc., and Walleye Capital LLC.
View insider buying and selling activity for Pacira BioSciences
or or view top insider-buying stocks.

How do I buy shares of Pacira BioSciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $57.99.

How much money does Pacira BioSciences make?

Pacira BioSciences has a market capitalization of $2.58 billion and generates $429.65 million in revenue each year. The company earns $145.52 million in net income (profit) each year or $1.30 on an earnings per share basis.

How many employees does Pacira BioSciences have?

Pacira BioSciences employs 624 workers across the globe.

What is Pacira BioSciences' official website?

The official website for Pacira BioSciences is www.pacira.com.

Where are Pacira BioSciences' headquarters?

Pacira BioSciences is headquartered at 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at (973) 254-3560 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.